/

INO

Inovio Pharmaceuticals, Inc.Closed

0.9982−0.11 −9.67%USD

NasdaqCM · as of Oct 13, 16:00 ET · 15m delayAfter hours 1.01 +1.18%

Open

1.11

Prev close

1.11

Day range

0.95001.11

52-week range

0.56002.72

Volume

8.46M2.15×

Mkt cap

103.21M

P/E ttm

—

Fwd P/E

-2.27

EPS ttm

-0.9000

Div yield

0.00%

Earnings

Aug 12, 2026

From 52w high

−63.30%

Price Chart

Yahoo Finance · delayed

INOOct 13, 2026O 1.11H 1.11L 0.95C 1.00−0.11 (−9.91%)Vol 8.47M

SMA 501.14
SMA 2001.32

1Y change −59.51% since Oct 13, 2025 close539 bars loadedTimes in America/New_YorkDraw from the left toolbar · click a drawing to edit · right-click for alerts and export

INO Inovio Pharmaceuticals, Inc. · Last Guard Finance

DES

Key Statistics

Yahoo Finance

Performance

1 week: −11.50%
1 month: −20.00%
3 months: −13.79%
6 months: −9.91%
Year to date: −42.53%
1 year: −59.51%

Valuation & ownership

Market cap: 103.21M
Enterprise value: 74.54M
P/E (ttm): —
Forward P/E: -2.27
PEG ratio: —
Price / book: 18.83
Price / sales (ttm): —
EV / EBITDA: -0.96
EPS (ttm): -0.9000
EPS (forward): -0.4400
Beta (5y monthly): 1.61
Dividend yield: 0.00%
Payout ratio: 0.00%
Shares outstanding: 103.40M
Float: 95.79M
Short % of float: 22.33%
Short ratio (days): 6.87
Held by insiders: 0.33%
Held by institutions: 46.06%
Avg volume (3m): 3.94M
50-day average: 1.14
200-day average: 1.32
52-week change: −59.51%
S&P 500 52-week: +17.03%

Technicals (daily)

RSI (14): 36.6
vs 50-day SMA: −12.54%
vs 200-day SMA: −23.98%
50 / 200-day trend: ▼ 50 below 200
MACD vs signal: ▼ below
ATR (14) % of price: 8.99%
Realised vol (20d, ann.): 72.8%
From 52-week high: −63.24%
From 52-week low: +78.57%

ANR

Analyst Consensus

3 analysts

Consensus

—

Mean target

3.17

+217.24% implied

Low 2.50Median 3.00High 4.00

Recommendation trend

Now2 / 1 / 0
1m ago1 / 2 / 0

DES

About Inovio Pharmaceuticals, Inc.

Yahoo Finance profile

Inovio Pharmaceuticals, Inc., a biotechnology company, focuses on the discovery, development, and commercialization of DNA medicines to treat and protect people from diseases associated with human papillomavirus (HPV), cancer, and infectious diseases. Its DNA medicines platform uses SynCon, to help engineer precisely designed plasmid DNA plasmids, as well as CELLECTRA smart devices technology that facilitates delivery of the DNA plasmids. The company's lead product candidate is INO-3107 for HPV-related recurrent respiratory papillomatosis and is under Phase 1/2 trial. Its products in pipeline include VGX-3100 for the treatment of HPV-related cervical high-grade squamous intraepithelial lesions; INO-3112 for the treatment of HPV-related Oropharyngeal squamous cell carcinoma and is under Phase 2 trial; INO-5401 for the treatment of glioblastoma multiforme and is under Phase 2 trial; INO-4201 for Ebola Virus Disease and is under Phase 1b trial; INO-4800 for COVID-19 and is under Phase 2/3 trial; and INO-6160 for the treatment of human immunodeficiency virus and is under Phase 1 trial. The company's partners and collaborators ApolloBio Corporation, AstraZeneca, Coherus Biosciences, Defense Advanced Research Projects Agency, HIV Vaccines Trial Network, Kaneka Eurogentec, National Institutes of Health, National Institute of Allergy and Infectious Diseases, Plumbline Life Sciences, Regeneron Pharmaceuticals, Richter BioLogics, the University of Pennsylvania, and The Wistar Institute. The company was incorporated in 1983 and is headquartered in Plymouth Meeting, Pennsylvania.

Sector: Healthcare
Industry: Biotechnology
Employees: 112
Headquarters: Plymouth Meeting, PA, United States
Website: inovio.com
Officers

SEAS

Seasonality · INO

2007–2026 · monthly returns

Strongest month Jul +11.58%Weakest month Sep −6.74%Averages use completed years only. Past seasonality doesn't predict future returns.

Year	Jan	Feb	Mar	Apr	May	Jun	Jul	Aug	Sep	Oct	Nov	Dec	Year
2026	-6.3	11.0	-3.9	-35.6	17.0	-16.0	-38.2	86.8	-3.9	-18.2			−42.6%
2025	14.2	-5.3	-17.7	19.0	3.1	2.0	-30.4	66.9	-1.3	0.4	-12.3	-15.5	−4.9%
2024	-11.9	64.4	56.7	-17.5	-11.5	-20.2	31.9	-32.3	-19.9	-8.7	-18.2	-57.6	−70.1%
2023	6.4	-24.1	-34.9	-6.1	-22.1	-25.0	17.8	-15.1	-13.3	-7.7	8.3	30.8	−67.3%
2022	-17.0	-21.7	10.8	-24.0	-31.5	-7.5	14.5	15.7	-24.5	24.9	-5.6	-23.5	−68.7%
2021	44.1	-12.9	-16.4	-26.6	10.9	22.8	-9.4	2.9	-17.1	-0.3	1.4	-31.1	−43.6%
2020	37.3	-5.5	73.8	61.7	22.6	82.7	-27.9	-38.3	-3.3	-15.1	24.1	-27.6	+168.2%
2019	25.2	-26.9	1.9	0.8	-36.4	23.0	-6.1	-21.7	-5.1	3.9	18.3	31.0	−17.5%
2018	10.4	-10.1	14.9	-6.8	8.4	-17.6	2.3	31.2	5.7	-11.3	8.5	-25.2	−3.1%
2017	-4.9	6.8	-6.1	-5.0	20.0	3.8	-29.1	6.8	6.7	-8.0	-21.3	-10.0	−40.5%
2016	-0.6	-5.7	38.3	20.3	8.0	-18.4	6.9	-7.2	1.6	-30.6	9.4	-2.0	+3.3%
2015	-9.2	-15.1	15.3	0.0	3.1	-3.0	-10.7	2.7	-22.8	9.5	17.1	-9.3	−26.8%
2014	-11.0	27.5	1.2	-28.8	-5.1	20.1	-6.6	4.9	-7.0	15.3	-14.8	-5.2	−20.9%
2013	32.0	4.5	-13.0	1.7	11.5	17.6	118.7	-2.9	21.8	-16.4	21.4	38.1	+480.0%
2012	58.1	-14.7	15.5	-19.4	-22.2	9.5	4.3	14.6	7.3	22.0	-26.4	-5.7	+16.3%
2011	10.4	-7.1	-6.8	-13.6	-18.9	-22.1	6.7	12.5	-20.8	19.3	-23.5	-17.3	−62.6%
2010	-12.3	45.0	-9.0	4.5	-15.9	-12.1	-1.0	-22.8	60.3	-9.6	4.4	-2.5	+0.9%
2009	-3.8	-30.0	11.4	-5.1	62.2	33.3	161.2	4.8	-28.3	-33.8	26.9	-13.6	+119.2%
2008	-4.3	4.5	4.3	-8.3	-11.4	38.5	-5.6	-5.9	-35.4	-40.3	-48.6	173.7	−43.5%
2007	-2.1	0.3	0.3	16.7	-4.2	-22.7	-17.9	-13.0	-32.5	-17.0	-17.9	0.0	−72.0%

INSD

Insider Activity · INO

Market-wide insider buying →Congress trades →SEC Form 4 filings via Yahoo Finance

Buys, 6 months

0 shares

Sells, 6 months

— shares

Net shares

Net change in insider shares

—

Date	Insider	Transaction	Shares	Value
May 19, 2026	Humeau Laurent MOfficer	—	6K	—
May 19, 2026	Kies Peter DChief Financial Officer	—	8.7K	—
May 19, 2026	Shea Jacqueline ElizabethChief Executive Officer	—	28.3K	—
May 19, 2026	Sumner Michael JohnOfficer	—	9.4K	—
May 14, 2026	Humeau Laurent MOfficer	—	4.8K	—
May 14, 2026	Kies Peter DChief Financial Officer	—	4.8K	—
May 14, 2026	Shea Jacqueline ElizabethChief Executive Officer	—	17.7K	—
May 14, 2026	Sumner Michael JohnOfficer	—	2.4K	—
Mar 30, 2026	Sumner Michael JohnOfficer	—	4.3K	—
Feb 25, 2026	Weiner David BDirector	—	972	—
Feb 25, 2026	Humeau Laurent MOfficer	—	12.4K	—
Feb 25, 2026	Kies Peter DChief Financial Officer	—	15.6K	—
Feb 25, 2026	Shea Jacqueline ElizabethChief Executive Officer	—	47K	—
Feb 25, 2026	Sumner Michael JohnOfficer	—	16.6K	—
Jun 29, 2025	Sumner Michael JohnOfficer	—	2.9K	—
May 20, 2025	Weiner David BDirector	—	2.2K	—
May 20, 2025	Dansey Roger DDirector	—	2.2K	—
May 20, 2025	Miller Ann Calby M.D.Director	—	2.2K	—
May 20, 2025	Benito Simon XDirector	—	2.2K	—
May 20, 2025	Shepard Jay P.Director	—	2.2K	—

13F

Investors Holding INO

latest 13F filings of 29 followed managers

Investors holding INO
Investor	Value	Of portfolio	Shares	Change	Quarter
Renaissance Technologies	$397.5K	0.00%	361.34K	−44%	Q2 2026

From each investor's quarterly 13F filing with the SEC: positions at the quarter's end, reported up to 45 days later. All investors

INO

Price Chart

Keyboard shortcuts & functions

Anywhere

Command line

Charts (click the chart first)

Function codes

INO

Price Chart

Key Statistics

Performance

Valuation & ownership

Technicals (daily)

Analyst Consensus

About Inovio Pharmaceuticals, Inc.

Seasonality · INO

Insider Activity · INO

Congress Trades · INO

Investors Holding INO

Investors Holding INO

Congress Trades · INO

Insider Activity · INO

Seasonality · INO

Key Statistics

Performance

Valuation & ownership

Technicals (daily)

Analyst Consensus

About Inovio Pharmaceuticals, Inc.

Financial Snapshot

Earnings & Dividends

News